摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5-di(benzylthio)-1,3,4-thiadiazole | 10106-21-5

中文名称
——
中文别名
——
英文名称
2,5-di(benzylthio)-1,3,4-thiadiazole
英文别名
2,5-bis(benzylthio)-1,3,4-thiazole;2,5-dibenzylthio-1,3,4-thiadiazole;2,5-bis-benzylsulfanyl-[1,3,4]thiadiazole;bis-benzylmercapto-[1,3,4]thiadiazole;Bis-benzylmercapto-[1,3,4]thiadiazol;2,5-bis-benzylsulfanyl[1,3,4]thiadiazole;2,5-Bis(benzylsulfanyl)-1,3,4-thiadiazole
2,5-di(benzylthio)-1,3,4-thiadiazole化学式
CAS
10106-21-5
化学式
C16H14N2S3
mdl
MFCD00545905
分子量
330.499
InChiKey
HQOJMWWJCILSIP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    21
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    105
  • 氢给体数:
    0
  • 氢受体数:
    5

SDS

SDS:f3439132d169e9597f12b07390e9e9e1
查看

反应信息

  • 作为反应物:
    描述:
    2,5-di(benzylthio)-1,3,4-thiadiazole1,4-二氮杂双环[3.2.2]壬烷N,N-二异丙基乙胺 作用下, 反应 15.0h, 生成 4-(5-benzenesulfanyl-[1,3,4]-thiadiazol-3-yl)-1,4-diaza-bicyclo[3.2.2]nonane fumaric acid salt
    参考文献:
    名称:
    [EN] DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS
    [FR] DERIVES D'ARYLE DIAZABICYCLIQUES CONSTITUANT DES MODULATEURS DES RECEPTEURS CHOLINERGIQUES
    摘要:
    这项发明涉及新型的二氮杂双环芳基衍生物,发现它们在尼古丁乙酰胆碱受体上是胆碱能配体,并且调节单胺受体和转运体。由于它们的药理特性,本发明的化合物可能对治疗与中枢神经系统(CNS)的胆碱能系统、外周神经系统(PNS)、平滑肌收缩相关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症相关的疾病或障碍、疼痛以及由于滥用化学物质而导致的戒断症状等多种疾病或障碍具有用处。
    公开号:
    WO2005074940A1
  • 作为产物:
    描述:
    S-benzyldithiocarbazate三氟乙酸 作用下, 以 乙醇 为溶剂, 反应 4.0h, 以79%的产率得到2,5-di(benzylthio)-1,3,4-thiadiazole
    参考文献:
    名称:
    通过酸催化取代二硫代氨基甲酸酯的分子间环化反应合成新型 2,5-双(取代硫代)-1,3,4-噻二唑作为可能的 2019-nCoV 主要蛋白酶抑制剂
    摘要:
    完成了特权药物支架,2,5-双(取代硫代)-1,3,4-噻二唑的方便和容易的合成。水合肼与二硫化碳和取代的烷基/芳基氯在碱性介质中的反应以高收率得到S-取代的烷基/芳基二硫代氨基甲酸酯。这些二硫代氨基甲酸酯与四氟乙酸反应后,经过独特的酸催化分子间环化反应,得到新型 2,5-双(取代硫代)-1,3,4-噻二唑。操作简单、收率高是这些反应的特点。这些化合物的特征基于物理化学和光谱(FT-IR、ESI 质量、1 H、13 C 和 DEPT 135° 13 C { 1H} NMR)研究。化合物 2b 在点群为 P bca 的正交晶系中结晶。使用 DFT/B3LYP/6-311 G (d,p) 理论水平,进行了 HOMO-LUMO 能隙和分子静电势 (MEP) 分析。HOMO-LUMO 能隙允许计算分子的化学硬度、化学惰性、电负性和亲电指数,这描述了它们潜在的动力学稳定性和反应性。2b-2e 与 2019-nCoV
    DOI:
    10.1016/j.molstruc.2021.132252
点击查看最新优质反应信息

文献信息

  • Design, Synthesis, and Structure−Activity Relationship of Substrate Competitive, Selective, and in Vivo Active Triazole and Thiadiazole Inhibitors of the c-Jun N-Terminal Kinase
    作者:Surya K. De、John L. Stebbins、Li-Hsing Chen、Megan Riel-Mehan、Thomas Machleidt、Russell Dahl、Hongbin Yuan、Aras Emdadi、Elisa Barile、Vida Chen、Ria Murphy、Maurizio Pellecchia
    DOI:10.1021/jm801503n
    日期:2009.4.9
    We report comprehensive structure−activity relationship studies on a novel series of c-Jun N-terminal kinase (JNK) inhibitors. The compounds are substrate competitive inhibitors that bind to the docking site of the kinase. The reported medicinal chemistry and structure-based optimizations studies resulted in the discovery of selective and potent thiadiazole JNK inhibitors that display promising in
    我们报告了一系列新型 c-Jun N 末端激酶 (JNK) 抑制剂的综合构效关系研究。这些化合物是与激酶对接位点结合的底物竞争性抑制剂。报道的药物化学和基于结构的优化研究导致发现了选择性和有效的噻二唑 JNK 抑制剂,这些抑制剂在胰岛素不敏感的小鼠模型中显示出有希望的体内活性。
  • Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators
    申请人:Peters Dan
    公开号:US20080227773A1
    公开(公告)日:2008-09-18
    This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemicals substances.
    本发明涉及新型的二氮杂双环芳基衍生物,这些衍生物被发现是乙酰胆碱受体的胆碱能配体,以及单胺类受体和转运体的调节剂。由于它们的药理特性,本发明的化合物可能对治疗与中枢神经系统(CNS)和外周神经系统(PNS)的胆碱能系统相关的疾病或障碍,平滑肌收缩相关的疾病或障碍,内分泌疾病或障碍,神经退行性疾病或障碍,炎症、疼痛以及因滥用化学物质的终止而引起的戒断症状等多种疾病或障碍具有用处。
  • DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS
    申请人:PETERS Dan
    公开号:US20100113428A1
    公开(公告)日:2010-05-06
    This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
    本发明涉及一种新型的二氮杂双环芳基衍生物,其在尼古丁酸乙酰胆碱受体上被发现为胆碱能配体,并且是单胺类受体和转运体的调节剂。由于它们的药理学特性,本发明的化合物可能有用于治疗与中枢神经系统(CNS)的胆碱能系统、外周神经系统(PNS)、平滑肌收缩相关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症相关的疾病或障碍、疼痛以及化学物质滥用终止引起的戒断症状等多种疾病或障碍的治疗。
  • Diazabicyclic aryl derivatives as cholinergic receptor modulators
    申请人:NeuroSearch A/S
    公开号:EP2172469A1
    公开(公告)日:2010-04-07
    This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
    本发明涉及新型重氮双环芳基衍生物,它们是烟碱乙酰胆碱受体的胆碱能配体,也是单胺受体和转运体的调节剂。由于其药理特性,本发明化合物可用于治疗各种疾病或紊乱,如与中枢神经系统(CNS)、周围神经系统(PNS)的胆碱能系统有关的疾病或紊乱、与平滑肌收缩有关的疾病或紊乱、内分泌疾病或紊乱、与神经变性有关的疾病或紊乱、与炎症有关的疾病或紊乱、疼痛以及因终止滥用化学物质而引起的戒断症状。
  • Sandstroem,J., Acta Chemica Scandinavica (1947), 1961, vol. 15, p. 1295 - 1302
    作者:Sandstroem,J.
    DOI:——
    日期:——
查看更多